Mechanism of Action: Kallikrein Inhibitors

Drugs with Mechanism of Action: Kallikrein Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	11,198,691
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	11,084,809		Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	10,611,758
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	10,364,238		Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	11,001,578		Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes	11,230,537		Y	Y
Kalvista	EKTERLY	sebetralstat	TABLET;ORAL	219301-001	Jul 3, 2025		RX	Yes	Yes

Last updated: June 19, 2026

Market Dynamics and Patent Landscape for Kallikrein Inhibitors: What Patents Protect, When Exclusivity Ends, and Where Generic/Biosimilar Risk Emerges

Kallikrein inhibitors span multiple therapeutic targets and modalities, including small-molecule serine protease inhibitors (e.g., kallikrein 1/3/7 pathways in dermatology and pain signaling), plasma kallikrein blockade (hereditary angioedema and related complement-like cascades), and investigational tissue kallikrein programs. The patent landscape is fragmented by indication, target subtype (KLK1, KLK2, KLK3, KLK7, KLK11, plasma kallikrein/KLK1 equivalents, etc.), and formulation or method-of-use claims. Market exclusivity timelines depend on (1) whether the product is biologic vs small molecule vs combination therapy, (2) jurisdictional patent filing dates, and (3) Orange Book or national registry coverage.

This analysis maps the commercial and legal dynamics for kallikrein inhibitors, identifies the main IP protection themes that control market entry, and outlines the practical generic entry risks for each commercial segment where regulatory status and exclusivity can be anchored to published records.

Note: This write-up focuses on the actionable patent-IP structure and market dynamics for kallikrein inhibitors as a class, and does not enumerate a complete “all kallikrein inhibitor patents” global corpus. The controlling bottlenecks for entry typically come from active-ingredient process claims plus formulation, dosing regimen, and method-of-treatment patents.

---

Which drugs count as “kallikrein inhibitors” and how do their mechanisms differ?

Kallikrein inhibitors are not a single regulatory class; they are a mechanism label spanning different proteases and therapeutic contexts. Mechanism-driven patent barriers track these distinctions.

What kallikrein targets dominate commercial programs?

1. Plasma kallikrein (PKa) / contact system blockade

   • Used to suppress bradykinin-mediated pathways central to hereditary angioedema (HAE).
   • Patent estates often combine composition, dosing regimens, and manufacturing/process claims.

2. Tissue kallikreins (KLKs) in oncology, dermatology, and inflammation

   • Includes programs targeting KLK family members implicated in tumor invasion, keratinocyte signaling, and inflammatory cascades.
   • Patent coverage is typically dominated by method-of-use claims tied to biomarkers and specific patient populations, plus formulation.

3. Kallikrein 1/3/7 pathways in urology/dermatology

   • These can be tied to prostate-related biology (KLK3/PSA-related biology) or skin barrier and inflammatory signaling (KLK7-related).
   • Patent estates tend to be narrower on chemistry but broader on clinical use definitions and administration routes.

How do modalities change the patent and exclusivity map?

• Small molecules: control entry via active-ingredient composition claims, process claims, crystal/polymorph claims, and dosing regimen method claims.
• Biologics: control entry via primary sequence claims (if any), neutralizing epitope/functional claims, manufacturing process claims, and method-of-use.
• Combination therapies: control entry via fixed-dose combinations, titration schedules, and patient-selection claims.

---

What is the Orange Book status of kallikrein inhibitors in the US?

Featured-snippet answer: Orange Book status depends on each specific product. Kallikrein inhibitors with US approvals usually have listings for at least one patent family covering the active ingredient (or biologic equivalent), with additional patents covering formulation and methods of use. To determine the precise exclusivity and listed patents for a target product, the Orange Book must be checked by NDC and active ingredient.

What Orange Book listings typically look like for kallikrein inhibitors

• Drug substance patents
  • Composition of matter for the inhibitor core scaffold
  • Process and intermediate claims for synthesis
• Drug product patents
  • Tablet/capsule/suspension formulations
  • Extended-release or stabilized salt forms
  • Manufacturing controls that prevent bioequivalence design-arounds
• Method-of-use patents
  • Dosing regimen and titration schedule
  • Indication-specific use (HAE attack prevention vs acute treatment; oncology staging and patient biomarkers; dermatology lesion types)

How do Orange Book listings affect Paragraph IV risk?

• If Orange Book lists multiple patents with staggered expiration, generics can challenge one or more patents via Paragraph IV while still waiting out non-challenged patents.
• In kallikrein inhibitor programs, method-of-use and formulation patents are often the most relevant barriers after the drug substance term narrows.

---

When does exclusivity end for kallikrein inhibitor drugs?

Featured-snippet answer: Exclusivity is a function of patent expiration (composition and formulation) and regulatory exclusivity (including orphan designation protections where applicable). The “end date” is rarely a single date because multiple patent families and regulatory exclusivity periods stack.

Typical exclusivity stack for kallikrein inhibitor launches

• Regulatory exclusivity
  • Orphan drug exclusivity: 7 years (if applicable)
  • New chemical entity (NCE): 5 years (if applicable)
• Patent term
  • Composition of matter: longest from earliest non-provisional filing, adjusted for patent term adjustment
  • Formulation/polymorph: often later filed
  • Method-of-use: frequently late-stage filed, sometimes after clinical readouts

Why kallikrein inhibitors often see “late” entry risks

• Late-stage filings target:
  • Specific dosing regimens and patient subsets
  • Formulation improvements for stability and bioavailability
  • Crystalline form and solid-state controls

---

What patents protect plasma kallikrein inhibitors for hereditary angioedema (HAE)?

Featured-snippet answer: For HAE-oriented plasma kallikrein inhibitors, patent estates typically cover (1) inhibitor chemistry (composition and process), (2) solid-state and formulation, and (3) method-of-treatment claims tied to dosing regimens and attack prevention.

Common patent claim themes in plasma kallikrein programs

1. Composition of matter
   • Active ingredient and structural variants
   • Salt forms and solvates (if relevant)
2. Process for synthesis
   • Specific intermediates and reaction conditions
   • Purification steps controlling impurities
3. Formulation
   • Stability under storage and at physiologic pH
   • Administration device compatibility for certain delivery systems
4. Method of use
   • Prevention of HAE attacks
   • Treatment of acute attacks
   • Dosing schedule and patient monitoring parameters
5. Manufacturing
   • Scale-up conditions and in-process controls

How does litigation typically concentrate in this space?

• Often centers on whether a generic can:
  • Avoid literal infringement of formulation or method-of-use patents
  • Design around process-related claims
  • Enter despite Orange Book listing strategy by the brand

---

What patents protect tissue kallikrein inhibitors for oncology and dermatology?

Featured-snippet answer: Tissue kallikrein inhibitor estates often rely on method-of-use plus biomarker-defined populations and formulation.

Key patent themes

• Method-of-treatment claims
  • Patient-selection criteria by biomarker expression of KLKs
  • Line-of-therapy definitions and combination contexts
• Combination therapy patents
  • Co-administration with standard-of-care (SOC) regimens
  • Sequencing and dosing timing
• Formulation and route-of-administration
  • Topical vs oral distinctions
  • Sustained exposure or targeted delivery

How biomarker claims change generic risk

• If claims require specific biomarker thresholds, non-identical indication labeling can reduce direct infringement but may still trigger design-around litigation.

---

How many patents cover kallikrein inhibitors and what is the patent “density” by asset type?

A reliable “count” requires product-by-product registry extraction from Orange Book, USPTO, and EPO and cannot be generalized without exact identifiers.

Patent density pattern observed across kallikrein programs (class-level)

• Drug substance families: usually 1 main scaffold family plus improvements.
• Drug product families: 1 to multiple families for stability, polymorph, and dosage form.
• Method-of-use families: can outnumber composition patents, particularly for late-stage indication expansion.

Practical implication for investors and litigators

• The most litigated patents are often not the earliest ones.
• For market entry timing, the relevant “blocking patents” are the ones still listed or still in force in the entry jurisdiction at the intended generic launch date.

---

Which companies are challenging kallikrein inhibitor patents and how do Paragraph IV strategies work?

Featured-snippet answer: Challenges typically come from generic manufacturers targeting the most vulnerable late-expiring patents (formulation or method-of-use) and seeking an engineered “launch at risk” date.

Typical Paragraph IV patterns in kallikrein estates

• Challenge multiple patents to force an earlier settlement.
• Focus on:
  • formulation and dosing claims that can be attacked through narrow claim construction
  • method-of-use claims that may be vulnerable to differences in labeling or indication
• Generic entry often becomes a settlement-driven event rather than a fully litigated outcome.

Settlement-driven launch timing

• Settlements frequently tie brand and generic entry to:
  • specific launch dates
  • carve-outs excluding certain strengths or delivery forms
  • stipulations about non-infringement or agreed “non-overlap” periods

---

What generic entry risks exist for oral vs injectable kallikrein inhibitors?

Featured-snippet answer: Oral formulations introduce solid-state and bioavailability barriers; injectable formats add manufacturing controls and stability claims.

Oral inhibitors: typical entry barriers

• Polymorph/crystal form claims
• Bioequivalence-driven formulation differences still risk infringement if claims cover functional parameters
• Process and impurity profiles

Injectable inhibitors: typical entry barriers

• Sterility and stability manufacturing claims
• Specific concentration ranges and excipient systems
• Device-adjacent IP (where applicable)

---

How do formulation patents for kallikrein inhibitors affect bioequivalence design-arounds?

Featured-snippet answer: Formulation patents can block bioequivalent entry even when the active ingredient composition expires or is successfully designed around.

Formulation claim types that matter

• Solid-state form and polymorph claims
• Particle size distributions and milling methods
• Excipients with specific roles (stabilizers, surfactants, buffering systems)
• Dissolution profile specifications

Litigation leverage created by formulation patents

• If the formulation is protected by broad Markush-type claims, design-arounds narrow quickly.
• If the claims are tied to specific parameter ranges, challengers attempt to move outside the defined range while still passing bioequivalence.

---

What method-of-use patents for kallikrein inhibitors are most likely to block labeling?

Featured-snippet answer: For kallikrein inhibitors, method-of-use patents most often block when labeling would induce infringement of a regimen claim (dose, frequency, duration, or patient selection).

Method-of-use claim elements that create blocking risk

• Regimen definition: dose, schedule, and duration
• Patient inclusion/exclusion: biomarkers, severity scales, prior therapies
• Combination contexts: “in combination with” another drug, including sequencing

Labeling carve-outs and “non-infringing use”

• If method-of-use claims are tied to an indication, changing the label can reduce infringement risk.
• However, brand settlements and “intent-to-infringe” arguments can still emerge if the generic’s marketing and instruction align with the claimed regimen.

---

How do patent expiration dates translate into generic launch scenarios?

Featured-snippet answer: Launch timing is determined by the last unexpired blocking patent in the relevant jurisdiction and whether a settlement authorizes entry before full expiration.

Scenario framework for market entry (practical)

1. Drug substance expires
   • Entry still blocked by formulation and method-of-use patents
2. Formulation expires
   • Remaining method-of-use patents still require label or regimen carve-outs
3. Method-of-use expires
   • Generics can often align labeling more closely to brand and reduce litigation risk
4. Settlement accelerates entry
   • Settlement can preempt final patent expiration outcomes

Why last-to-expire patents matter for kallikrein inhibitors

• Late-stage formulation and method-of-use filings keep a “long tail.”
• Kallikrein programs often pursue indication expansion, creating additional method-of-use families.

---

What biosimilar risk exists for kallikrein inhibitors?

Featured-snippet answer: Biosimilar risk is limited to kallikrein inhibitors that are biologics or protein-based. Many “kallikrein inhibitor” market assets are small molecules, where Paragraph IV generics apply rather than biosimilar pathways.

Biosimilar-like considerations for non-small molecules

• If a kallikrein inhibitor is antibody-derived, enzyme replacement-like, or other biologic:
  • exclusivity and patent barriers are governed by biologic-specific regulatory frameworks and patent estates
  • litigation typically addresses functional similarity, epitope or binding, and manufacturing/quality attributes

---

How does regulatory pathway choice affect patent strategy for kallikrein inhibitors?

Featured-snippet answer: FDA pathway selection influences the evidence timeline and drives when patents are filed (composition vs clinical-use vs formulation improvements).

Regulatory pathway dynamics

• 505(b)(1) / 505(b)(2)
  • Can enable label changes and later patent filings around clinical use
• 505(j)
  • Drives Paragraph IV certification and sets the litigation clock
• Orphan designation
  • Adds regulatory exclusivity layers, affecting settlement leverage

---

Key litigation inflection points in kallikrein inhibitor patent estates

Featured-snippet answer: Litigation in kallikrein inhibitor estates concentrates around claim construction for method-of-use and formulation patents and whether design-arounds avoid infringement while maintaining bioequivalence and label consistency.

Common dispute areas

• Whether an alternative dosing regimen avoids a regimen claim
• Whether a different solid-state form infringes Markush-style language
• Whether process changes avoid process claims (often hard to fully avoid at scale)

Settlement structure that shapes market access

• Most settlements are calendar-driven with:
  • entry dates
  • partial carve-outs
  • stipulations on non-infringement or limited exclusivity

---

Competitive landscape: How do kallikrein inhibitors compare across indications?

Featured-snippet answer: Competitive intensity is higher where:

• the target protein is well-validated,
• the dosing regimen is simple,
• and the patent estate is concentrated in early composition claims rather than long-tail method-of-use and formulation.

Segment comparison lens

• HAE/contact system inhibitors: fewer competitors, higher patent-driven gating.
• Oncology tissue kallikrein programs: development stage and biomarker-driven differentiation drive narrower but strategic method-of-use claims.
• Dermatology/skin inflammation: topical vs oral route claims and formulation dominate entry barriers.

---

Key Takeaways

• Kallikrein inhibitor IP is not one estate; it is indication- and target-subtype-specific across plasma contact-system biology and tissue kallikreins.
• Market exclusivity and generic launch timing are controlled less by earliest composition patents and more by formulation and method-of-use patents that keep a long tail.
• Paragraph IV challenges generally target late-expiring formulation and regimen claims, with settlements often determining launch dates.
• Biosimilar risk applies only where a kallikrein inhibitor is biologic; many commercial assets are small molecules, making 505(j) the main entry channel.
• Competitive dynamics track patent tail risk: assets with long-tail method-of-use and formulation coverage face slower generic uptake even when core composition claims expire.

---

FAQs

Which patent claim types most often block generic entry for kallikrein inhibitors?

Formulation (solid-state, excipient system, dissolution/bioavailability) and method-of-use regimen claims (dose, schedule, patient selection) most frequently block entry despite active-ingredient expiration.

Do kallikrein inhibitor settlements typically accelerate launch or restrict labeling?

They typically do both: a calendar entry date plus label/regimen carve-outs tied to non-infringement positions.

How can a generic avoid a method-of-use patent on a kallikrein inhibitor?

By changing the label and induced dosing regimen so the claimed regimen is not practiced, and by aligning marketing and patient instructions away from the claimed population and schedule.

What makes formulation patents especially strong for kallikrein inhibitors?

They can cover multiple solid-state forms and functional parameters that are difficult to change while still meeting bioequivalence requirements.

Is the kallikrein inhibitor patent landscape stronger in HAE than in oncology?

Class-level enforcement tends to be strong in HAE because regulatory labeling is tightly tied to dosing regimens, which aligns with infringement pathways for method-of-use patents.

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
2. FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
3. USPTO. Patent Public Search. United States Patent and Trademark Office. https://ppubs.uspto.gov/